A	B	C	D	E	F	G	H	I
1	Main
2		Ortho Tri-Cyclen	norgestimate/ethinyl estradiol
3		Administration	Tablet
4			Combination (3) triphasic oral contraceptive containing .18mg,.215mg,25mg nogestimate and 0.035mg ethiny estradiol
5		IP	Approved 7/3/92, no unexpired patents
6
7		Ortho Tri-Cyclen Lo	norgestimate/ethinyl estradiol
8		Administration	Tablet
9			Combination (3) triphasic oral contraceptive containing .18mg,.215mg,25mg nogestimate and 0.025mg ethiny estradiol
10		IP	Approved 8/22/02, expires 6/9/19 (method patent)
11
12		Orhto-Cyclen	norgestimate/ethinyl estradiol
13		Administration	Tablet
14			Combination contraceptive product containing 0.250 mg norgestimate and 0.035 mg ethinyl estradiol.
15		IP	Approved 12/29/89
16
17		Ortho-Novum	norethindrone/ethinyl estradiol
18		Administration	Tablet
19			Combination oral contraceptive containing
20		IP	4 Patents early 1980's
21
22		Ortho Evra	norelgestromin/ethinyl estradiol transdermal system
23		Administration	Transdermal
24			Combination transdermal contraceptive patch containing 6 mg norelgestromin and 0.75 mg ethinyl estradiol
25		IP	Approved 11/20/01, Expires 11/20/15 (Method & Composition)
26
27		Hormonal Contraceptives	2001	2002	2003	2004	2005	2006	2007
28		US		#ERROR_#REF!	#ERROR_#REF!	#ERROR_#REF!	920	781	662
29		ROW		#ERROR_#REF!	#ERROR_#REF!	#ERROR_#REF!	216	235	236
30				#ERROR_#REF!	#ERROR_#REF!	#ERROR_#REF!	1136	1016	898
31
32		Q106: strong growth in ortho tri-cyclen lo. Ortho evra declined due to labeling changes and negative media coverage.